Arterial Remodeling Technologies (‘ART’) reported from the podium yesterday at ‘TCT 2013’ that the Company has successfully completed the 30-day milestone portion of the “ARTDIVA” (Arterial Remodeling Transient DIsmantling Vascular Angioplasty) clinical trial of its novel bioresorbable stent. ART’s next-generation bioresorbable stent is designed to promote positive arterial remodeling and then bioresorb (i.e., ‘disappear’).
Help employers find you! Check out all the jobs and post your resume.
